Company Registration No. 13665458 (England and Wales)
CYTOGENESIS LIMITED
Annual Report and Statement of Accounts
For the Period from 01 November 2022 to 31 October 2023

CYTOGENESIS LIMITED

Annual report and statement of accounts for the period ending 31/10/2023

CYTOGENESIS LIMITED

Financial statement for the period ended 31/10/2023

Company Information

1 Statutory Information
Company Number 13665458
Registered Office INTERNATIONAL HOUSE 36-38 CORNHILL
LONDON
EC3V 3NG
2 Directors
Directors who held office during the period were:
Dr Mark Andre Freyberg   
Dr Dirk Kaiser   
3 Principal Activity
Research and experimental development on biotechnologyInvestment in Biotechnology and pharma
4 Employees
Average number of employees, including directors, during the year was as follows:
2023 2
2022 2

CYTOGENESIS LIMITED

Financial statement for the period ended 31/10/2023

Statement of Financial Position

2023 2022
£ £
Fixed Assets 309,033 270,000
Current Assets 276,661 326,990
Creditors: amounts falling due within one year - -
Net Current Assets 276,661 326,990
Total assets less current liabilities 585,694 596,990
Creditors: amounts falling due after one year - -
Net Assets 585,694 596,990
Capital and reserves 585,694 596,990
For the period ending 31/10/2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
Approved by the Board on 17 July 2024
Dr Mark Andre Freyberg
Company Registration No. 13665458